SCHEMBL4742652

SCHEMBL4742652

O=c1cc(O)nc(-c2ccccc2)n1-c1ccccc1

nearest known ligand 0.54

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
APLNR P35414 2/20 0.54
HTT P42858 1/20 0.51
KMT2A Q03164 4/20 0.50
MEN1 O00255 3/20 0.50
GAA P10253 3/20 0.50
POLB P06746 3/20 0.47
HCAR1 Q9BXC0 1/20 0.47
RECQL P46063 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
TSHR P16473 2/20 0.46
MAPT P10636 3/20 0.46
CYP3A4 P08684 1/20 0.46
CYP2D6 P10635 1/20 0.46
ALDH1A1 P00352 3/20 0.46
HSP90AA1 P07900 1/20 0.46
CYP2C19 P33261 1/20 0.46
ESR1 P03372 1/20 0.45
ESR2 Q92731 1/20 0.45
LMNA P02545 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13800062 0.76 ALDH1A1 (0.58) HTTKMT2AMEN1GAAPOLB
SCHEMBL13167712 0.75 APLNR (0.68) APLNRHTTKMT2AMEN1GAA
SCHEMBL14142294 0.74 KMT2A (0.50) HTTKMT2AGAAPOLBHCAR1
SCHEMBL4737051 0.73 BCL2 (0.55) KMT2AMEN1GAARECQLSMN1; SMN2
SCHEMBL4739120 0.73 MAPT (0.49) HTTKMT2AMEN1GAAPOLB
SCHEMBL13125310 0.72 APLNR (0.80) APLNRHTTKMT2AMEN1GAA
SCHEMBL14571460 0.71 KMT2A (0.80) HTTKMT2AMEN1GAAPOLB
SCHEMBL17317042 0.71 APLNR (0.51) APLNRHTTKMT2AMEN1GAA
SCHEMBL4739172 0.71 APLNR (0.45) APLNRKMT2AMEN1GAAPOLB
SCHEMBL11540828 0.70 HCAR1 (0.50) HTTKMT2AMEN1GAAHCAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2008089051-A1 N-SUBSTITUTED GLYCINE DERIVATIVES: PROLYL HYDROXYLASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2008-07-24 WO disclosed
US-20080171756-A1 N-Substituted Glycine Derivatives: Prolyl Hydroxylase Inhibitors SMITHKLINE BEECHAM CORPORATION 2008-07-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080171756-A1 N-Substituted Glycine Derivatives: Prolyl Hydroxylase Inhibitors HIF1AN, EGLN2, EGLN3 APLNR 2034/4885HTT 2059/4885KMT2A 734/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.